Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Reexamination Certificate
2008-04-22
2008-04-22
Canella, Karen A. (Department: 1643)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
C424S138100, C424S172100, C424S173100, C424S174100, C424S001490, C424S009100, C424S009300, C435S007100, C435S007230
Reexamination Certificate
active
07361336
ABSTRACT:
Improved methods for treatment of cancer which involve the targeting of slow-growing, relatively mutationally-spared cancer stem line are provided. These methods are an improvement over previous cancer therapeutic methods because they provide for very early cancer treatment and reduce the likelihood of clinical relapse after treatment.
REFERENCES:
patent: 4894326 (1990-01-01), Matsuura et al.
patent: 5169835 (1992-12-01), Chan
patent: 5300500 (1994-04-01), Lee et al.
patent: 5489516 (1996-02-01), Broudy et al.
patent: 5530101 (1996-06-01), Queen et al.
patent: 5730982 (1998-03-01), Scheinberg
patent: 5808002 (1998-09-01), Buhring
patent: 5843633 (1998-12-01), Yin et al.
patent: 5980896 (1999-11-01), Hellstrom et al.
patent: 5990281 (1999-11-01), De Sauvage et al.
patent: 6004528 (1999-12-01), Bergstein
patent: 6129915 (2000-10-01), Wels et al.
patent: 6258939 (2001-07-01), Reiter et al.
patent: 6506881 (2003-01-01), Adair et al.
patent: 2001/0055751 (2001-12-01), Reiter et al.
patent: WO 90/12885 (1990-11-01), None
patent: WO 94/07474 (1994-04-01), None
patent: WO 95/07348 (1995-03-01), None
patent: WO 96/16668 (1996-06-01), None
patent: WO97/22360 (1997-06-01), None
patent: WO 97/35614 (1997-10-01), None
patent: WO 00/40229 (2000-07-01), None
patent: WO0240717 (2002-05-01), None
patent: WO 03/016470 (2003-02-01), None
Boucher et al, “The expression of trophoblastic cell markers by lung carcinomas”, Human Pathology, vol. 25, pp. 1201-1206, Nov. 1995.
Sakakibara et al, “Mouse Musashi1, a neural RNA-binding protein highly enriched in the mammalian CNS stem cell line”, Developmental biology, vol. 176, pp. 230-242, Jun. 1996.
Shtalrid et al (European Journal of Hematology, 1987, vol. 38, pp. 3-11).
Sachs (Cancer, 1991, vol. 67, pp. 2684-2694).
Metcalf (Hematology and Blood Transfusion, 1983, vol. 28, pp. 320-326).
Sherley et al (PNAS, 1995, vol. 92, pp. 136-140).
Door (Int Journal of Radiation Biology, 1997, vol. 72, pp. 635-643).
Chen et al (Blood, 1997, vol. 89, pp. 3345-3353).
The abstract of Mizutani, Sapporo Medical Journal, 1990, vol. 59, pp. 345-356.
Lin et al (Trends in Genetics, Jan. 1997, vol. 13, pp. 33-39).
Abstract of Taichman et al (Developmental Dynamics, 2002, vol. 225, pp. 166-175).
Abstract of Berezovska et al (Annals of the NY Academy of Sciences, 2000, vol. 920, pp. 223-226).
Stedman's Medical Dictionary, 27th Edition, 1995.
Verma et al (Nature, 1997, vol. 389, pp. 239-242).
Eck et al (Gene-Based Therapy, In: The Pharmacological Basis of Therapeutics, Goodman and Gilman, Ed.s, 1996, pp. 77-10.
Orkin et al ( “Report and Recommendation of the Panel to Assess the NIH Investment in Research on Gene Therapy”, NIH, 1995).
Heikinheimo et al (Blood, 1987, vol. 70, pp. 1279-1283).
Haynes et al (Virchows Arch, 1985, vol. 405, pp. 263-275).
Moroz et al (Pure and Applied Chemistry, 1993, vol. 65, pp. 1253-1264).
Rooney et al (Gene, 1988, vol. 71, pp. 439-449).
Miraglia et al (Blood, 1997, vol. 90, pp. 5013-5021).
Schlom (In: Molecular foundations of Oncology, Samuel Broder, Ed., 1991, pp. 95-134).
O'Brien and Morrow, Recent Clinical Developments in Gynecologic Oncology, 1983, Paul Morrow et al, Ed.s, pp. 167-180.
Abstract of Miyamura et al (Sapporo Igaku Zasshi, 1991, vol. 60, pp. 183-196).
Abstract of Ten Have-Opbroek et al (Histology and Histopathology, Apr. 1997, vol. 12, pp. 319-336).
Jones and Marasco, Advanced Drug Delivery Reviews, 1998, vol. 31, pp. 153-170.
Grim et al (Biochemical and biophysical Research Communications, 1998, vol. 250, pp. 699-703).
Tolcher et al (Clinical Cancer Research, 2002, vol. 8, pp. 2530-2535).
Cripps et al (Clinical Cancer Research. 2002, 8, pp. 2188-2192).
Marshall et al (Clinical Colorectal Cancer, 2004, vol. 4, pp. 268-274).
Oza et al (Gynecological Oncology, 2003, vol. 89, pp. 129-133).
James and Gibson (Blood, 1998, vol. 91, pp. 371-382).
Schultze et al (Trends in Immunology, 2004, vol. 25, pp. 659-664).
Bodey et al, (Anticancer Research, 2000, vol. 20, pp. 2665-2676).
Vile et al (Gene Therapy, 2000, vol. 7, pp. 2-8).
Gecz et al, Genomics, 1995, vol. 26, pp. 130-133.
Schmaucher and Magnuson, TIG, 1997, vol. 13, pp. 167-170.
Satijn et al, Mol Cell biol. 1997, vol. 17, pp. 6076-6086.
Stone et al, Nature, 1996, vol. 384, pp. 129-133.
Abstract of Pronzato et al (American Journal of Clinical Oncology, 1987, vol. 10, pp. 407-409).
Bonnet and Dick (1997).Nature Medicine3: 730-737.
Hope et al. (2003).Archives of Med. Res.34: 507-514.
Passegue et al. (2003).Proc. Natl. Acad. Sci. U.S.A.100: 11842-11849.
Otto (1997).Int. J. Exp. Path., 78: 291-310.
Beachy et al., 1997, “Multiple Roles of Cholesterol in Hedgehog Protein Biogenesis and Signaling.” Cold Spring Harbor Symposia on Quantitative Biology, vol. LXII 191-204.
Cao et al., 2006, “Glycogen synthase kinase-3β positively regulates the proliferation of human ovarian cancer cells.” Cell Res. 16:671-77.
Chen et al., 2004, “Activity-Dependent Internalization of Smoothened Mediated by β-Arrestin 2 and GRK2.” Science 306:2257-60.
Chiang et al., 1996, “Cyclopia and defective axial patterning in mice lacking Sonic hedgehog gene function.” Nature 383:407-13.
Degos et al., 1995, “All-trans-retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia.” Blood 85:2643-53.
Farber et al, 1984, “The multistep nature of cancer development.”Cancer Res 44:4217-23.
Farber et al, 1991, “Cellular adaptation in the origin and development of cancer.” Cancer Res. 51:2751-61.
Genbank Accession No. L37882, “Human frizzled gene product mRNA, complete cds.”, dow loaded from the web Mar. 20, 2007.
Fujii et al., 2007, “An Antagonist of Dishevelled Protein-Protein Interaction Suppresses β-Catenin-Dependent Tumor Cell Growth.” Cancer Res. 67(2):573-9.
Genbank Accession No. L37882, “Human frizzled gene product mRNA, complete cds.”, dow loaded from the web Mar. 20, 2007.
Harding et al., 1995, “A screen for modifiers of Deformed function in Drosophila.” Genetics 140:1339-52.
Hoang et al., 1996, “Primary structure and tissue distribution of FRZB, a novel protein related to Drosophila frizzled, suggest a role in skeletal morphorgenesis.”J. Biol. Chem. 271(42):26131-7.
Holliday et al., 1979, “A new theory of carcinogenesis.” Br. J. Cancer 40:513-22.
Hou et al, 1985, “Measurement of Antibody-Depndent Cell-Mediated Cytotoxicity by Hb-Enzyme Release Assay (Hb-ERA).” J. of Immunol. Methods 85:325-33.
Incardona et al., 1997, “Alterd Sonic Hedgehog Function is an Early Event in Cyclopamine-Induced Holoprosencephaly.” 30thAnnual Northwest Regional Developmental Biology Conference; Friday Harbor, Washington.
Jordan, 2007, “The leukemic stem cell.” Best Practice & Reearch Clinical Haematology 20(1):13-18.
Karhadkar et al., 2004, “Hedgehog signalling in prostrate regeneration, neoplasia and metastasis.” Nature 431:707-12.
Kennedy et al., 1984, “Timing of the steps in transformation of C3H 10T 1/2 cells by X-irradiation.” Nature 307:85-6.
Klein et al., 1996, “A molecular mechanism for the effect of lithium on development.” Proc. Natl. Acad. Sci 93(16):8455-9.
Mayr et al., 1997, “Fritz: a secreted frizzled-related protein that inhibits Wnt activity.” Mechan. Of Dev. 63:109-25.
Miyazaki et al., 2006, “Treatment of Eyelid Epithelial Neoplasm by Targeting Sonic Hedgehog Signaling: An Experimental Study.” Jpn J. Opthalmol 50:305-11.
Nagayama et al., 2005, “Therapeutic potention of antibodies against FZD10, a cell-surface protein for synovial sarcomas.” Oncogene 24:6201-12.
Pierce et al, 1988, “Tumors as caricatures of the process of tissue renewal: prospects for therapy by directing differentiation.” Cancer Res 48:1996-2004.
Pierce et al., 1978, “Cancer: a problem of developmental biology.” New Jersey, Prentice Hall.
Roes
Bergstein Ivan
Canella Karen A.
Jones Day
LandOfFree
Methods of cancer therapy targeted against a cancer stem line does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of cancer therapy targeted against a cancer stem line, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of cancer therapy targeted against a cancer stem line will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2781292